Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aytu Biopharma Inc (NQ: AYTU )

0.6700 -0.0200 (-2.90%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,418,413
Open 0.6552
Bid (Size) 0.6555 (1)
Ask (Size) 0.6650 (13)
Prev. Close 0.6900
Today's Range 0.6382 - 0.8097
52wk Range 0.4500 - 5.190
Shares Outstanding 38,574,875
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase... 
Via Benzinga
Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors
ENGLEWOOD, CO / ACCESSWIRE / June 29, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the appointment... 
From Aytu BioPharma, Inc.
Via AccessWire

Performance

YTD
-56.77%
-56.77%
1 Month
+16.12%
+16.12%
3 Month
-36.79%
-36.79%
6 Month
-50.37%
-50.37%
1 Year
-86.91%
-86.91%

More News

Read More
Aytu BioPharma Plans To Divest / Discontinue Non Core Assets
Via Benzinga
Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma: Q3 Earnings Insights
Via Benzinga
Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities
From Aytu BioPharma, Inc.
Via AccessWire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Delivery Technology
From Aytu BioPharma, Inc.
Via AccessWire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
54 Biggest Movers From Yesterday
Via Benzinga
Aytu BioPharma Announces Fast Track Designation Granted to AR101 for the Treatment of Vascular Ehlers-Danlos Syndrome
From Aytu BioPharma, Inc.
Via AccessWire
Exposures Product Safety
Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT(R)
From Aytu BioPharma, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Aytu BioPharma to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma to Participate in the 34th Annual Roth Conference
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma Announces Closing of $7.6 Million Registered Offering
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma Announces Pricing of $7.6 Million Registered Offering
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome
From Aytu BioPharma, Inc.
Via AccessWire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Aytu BioScience's Return On Capital Employed Overview
Via Benzinga
The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics
Via Benzinga
Aytu BioPharma Announces Business and Pipeline Progress and Reports Second Quarter 2022 Financial Results
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioScience, Inc. (NASDAQ:AYTU) Investor Alert: Investigation over Possible Violations of Securities Laws
Via SBWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.